Can-Fite BioPharma Ltd.CANFNYSE
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | 5.64% |
| Q4 2024 | 0.00% |
| Q3 2024 | -0.49% |
| Q2 2024 | 0.00% |
| Q1 2024 | 13.89% |
| Q4 2023 | -2.46% |
| Q3 2023 | -4.20% |
| Q2 2023 | -34.21% |
| Q1 2023 | -16.01% |
| Q4 2022 | 20.53% |
| Q3 2022 | 40.22% |
| Q2 2022 | -20.26% |
| Q1 2022 | -41.28% |
| Q4 2021 | 5.51% |
| Q3 2021 | 17.23% |
| Q2 2021 | 92.40% |
| Q1 2021 | -55.01% |
| Q4 2020 | 44.73% |
| Q3 2020 | -39.05% |
| Q2 2020 | -12.94% |
| Q1 2020 | -4.77% |
| Q4 2019 | 29.58% |
| Q3 2019 | 21.41% |
| Q2 2019 | 74.43% |
| Q1 2019 | -28.53% |
| Q4 2018 | 42.38% |
| Q3 2018 | 7.02% |
| Q2 2018 | 0.91% |
| Q1 2018 | -21.56% |
| Q4 2017 | 57.36% |
| Q3 2017 | -17.88% |
| Q2 2017 | 4.58% |
| Q1 2017 | -36.91% |
| Q4 2016 | 28.34% |
| Q3 2016 | 1.53% |
| Q2 2016 | 39.72% |
| Q1 2016 | -23.93% |
| Q4 2015 | 54.65% |
| Q3 2015 | -1.77% |